Key clinical point: Omalizumab reduces asthma exacerbations regardless of fixed airflow obstruction (FAO), but reductions were greatest in patients with high reversibility.
Major finding: The exacerbation relative rate reduction with omalizumab versus placebo was 6.0% in FAO-positive patients with low reversibility, 59.8% in FAO-positive patients with high reversibility, 17.4% in FAO-negative patients with low reversibility, and 44.3% in FAO-negative patients with high reversibility.
Study details: Post hoc analysis of a phase 3 trial of 848 patients with severe, uncontrolled asthma.
Disclosures: This research was funded by Genentech and Novartis. Dr. Hanania disclosed relationships with Genentech, Novartis, AstraZeneca, Boehringer Ingelheim, GSK, Regeneron, and Sanofi.
Hanania N et al. CHEST 2019. Abstract, doi: 10.1016/j.chest.2019.08.869.